Maravai Begin Period Cash Flow vs Stock Based Compensation Analysis

MRVI Stock

USD 5.77 0.16 2.70%

Maravai Lifesciences financial indicator trend analysis is infinitely more than just investigating Maravai Lifesciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Maravai Lifesciences is a good investment. Please check the relationship between Maravai Lifesciences Begin Period Cash Flow and its Stock Based Compensation accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Begin Period Cash Flow vs Stock Based Compensation

Begin Period Cash Flow vs Stock Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Maravai Lifesciences Begin Period Cash Flow account and Stock Based Compensation. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Maravai Lifesciences' Begin Period Cash Flow and Stock Based Compensation is 0.86. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of Maravai Lifesciences Holdings, assuming nothing else is changed. The correlation between historical values of Maravai Lifesciences' Begin Period Cash Flow and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Maravai Lifesciences Holdings are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Begin Period Cash Flow i.e., Maravai Lifesciences' Begin Period Cash Flow and Stock Based Compensation go up and down completely randomly.

Correlation Coefficient

0.86

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most indicators from Maravai Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Maravai Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

The Maravai Lifesciences' current Enterprise Value is estimated to increase to about 3.1 B, while Tax Provision is forecasted to increase to (1.5 M).

	2021	2022	2023	2024 (projected)
Interest Expense	30.3M	20.4M	45.9M	33.9M
Depreciation And Amortization	24.8M	38.1M	48.8M	33.8M

Interest Expense Depreciation And Amortization

Maravai Lifesciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets
Total Assets		0.9	0.97	0.88	0.87	0.94	0.87	0.58	0.25	-0.91	0.93	0.62	0.97	0.98	0.86	0.92	0.93	0.97	0.98	0.28	-0.93	0.93	0.95	0.61	0.94	0.99
Short Long Term Debt Total	0.9		0.83	0.95	0.72	0.94	0.74	0.79	0.48	-0.77	0.83	0.67	0.91	0.87	0.6	0.94	0.98	0.91	0.8	0.44	-0.98	0.69	0.86	0.83	0.94	0.92
Other Current Liab	0.97	0.83		0.8	0.93	0.91	0.84	0.56	0.1	-0.94	0.97	0.57	0.96	0.94	0.83	0.89	0.86	0.96	0.96	0.38	-0.87	0.91	0.88	0.55	0.89	0.97
Total Current Liabilities	0.88	0.95	0.8		0.59	0.86	0.63	0.6	0.66	-0.66	0.72	0.41	0.83	0.89	0.61	0.84	0.97	0.83	0.8	0.27	-0.96	0.67	0.9	0.67	0.86	0.86
Total Stockholder Equity	0.87	0.72	0.93	0.59		0.84	0.8	0.65	-0.19	-0.93	0.98	0.7	0.9	0.8	0.73	0.82	0.71	0.9	0.86	0.56	-0.72	0.83	0.69	0.59	0.8	0.89
Other Liab	0.94	0.94	0.91	0.86	0.84		0.88	0.73	0.26	-0.89	0.92	0.75	0.99	0.88	0.77	0.95	0.95	0.99	0.87	0.38	-0.94	0.82	0.85	0.69	0.99	0.96
Net Tangible Assets	0.87	0.74	0.84	0.63	0.8	0.88		0.47	-0.06	-0.95	0.83	0.79	0.9	0.81	0.87	0.89	0.79	0.9	0.86	0.11	-0.8	0.91	0.8	0.41	0.91	0.87
Property Plant And Equipment Net	0.58	0.79	0.56	0.6	0.65	0.73	0.47		0.18	-0.56	0.7	0.77	0.7	0.47	0.19	0.73	0.68	0.7	0.43	0.81	-0.69	0.32	0.39	0.95	0.71	0.66
Current Deferred Revenue	0.25	0.48	0.1	0.66	-0.19	0.26	-0.06	0.18		0.12	-0.01	-0.17	0.16	0.31	0.04	0.2	0.48	0.16	0.16	-0.1	-0.46	-0.01	0.41	0.34	0.27	0.21
Net Debt	-0.91	-0.77	-0.94	-0.66	-0.93	-0.89	-0.95	-0.56	0.12		-0.94	-0.74	-0.94	-0.85	-0.82	-0.92	-0.8	-0.94	-0.9	-0.35	0.81	-0.91	-0.79	-0.49	-0.9	-0.92
Retained Earnings	0.93	0.83	0.97	0.72	0.98	0.92	0.83	0.7	-0.01	-0.94		0.71	0.96	0.87	0.76	0.89	0.82	0.96	0.9	0.54	-0.83	0.85	0.78	0.66	0.88	0.96
Accounts Payable	0.62	0.67	0.57	0.41	0.7	0.75	0.79	0.77	-0.17	-0.74	0.71		0.75	0.5	0.5	0.75	0.62	0.75	0.54	0.41	-0.63	0.58	0.46	0.69	0.77	0.69
Cash	0.97	0.91	0.96	0.83	0.9	0.99	0.9	0.7	0.16	-0.94	0.96	0.75		0.91	0.81	0.95	0.93	1.0	0.92	0.4	-0.93	0.88	0.87	0.67	0.98	0.99
Non Current Assets Total	0.98	0.87	0.94	0.89	0.8	0.88	0.81	0.47	0.31	-0.85	0.87	0.5	0.91		0.86	0.87	0.91	0.91	0.98	0.2	-0.9	0.92	0.98	0.56	0.87	0.96
Non Currrent Assets Other	0.86	0.6	0.83	0.61	0.73	0.77	0.87	0.19	0.04	-0.82	0.76	0.5	0.81	0.86		0.69	0.69	0.81	0.92	-0.14	-0.68	0.96	0.87	0.21	0.77	0.83
Other Assets	0.92	0.94	0.89	0.84	0.82	0.95	0.89	0.73	0.2	-0.92	0.89	0.75	0.95	0.87	0.69		0.95	0.95	0.85	0.42	-0.96	0.8	0.84	0.7	0.96	0.94
Long Term Debt	0.93	0.98	0.86	0.97	0.71	0.95	0.79	0.68	0.48	-0.8	0.82	0.62	0.93	0.91	0.69	0.95		0.93	0.85	0.32	-1.0	0.76	0.91	0.71	0.96	0.93
Cash And Short Term Investments	0.97	0.91	0.96	0.83	0.9	0.99	0.9	0.7	0.16	-0.94	0.96	0.75	1.0	0.91	0.81	0.95	0.93		0.92	0.4	-0.93	0.88	0.87	0.67	0.98	0.99
Net Receivables	0.98	0.8	0.96	0.8	0.86	0.87	0.86	0.43	0.16	-0.9	0.9	0.54	0.92	0.98	0.92	0.85	0.85	0.92		0.17	-0.85	0.97	0.95	0.48	0.86	0.96
Good Will	0.28	0.44	0.38	0.27	0.56	0.38	0.11	0.81	-0.1	-0.35	0.54	0.41	0.4	0.2	-0.14	0.42	0.32	0.4	0.17		-0.34	0.04	0.04	0.72	0.32	0.36
Common Stock Total Equity	-0.93	-0.98	-0.87	-0.96	-0.72	-0.94	-0.8	-0.69	-0.46	0.81	-0.83	-0.63	-0.93	-0.9	-0.68	-0.96	-1.0	-0.93	-0.85	-0.34		-0.76	-0.9	-0.72	-0.96	-0.93
Common Stock Shares Outstanding	0.93	0.69	0.91	0.67	0.83	0.82	0.91	0.32	-0.01	-0.91	0.85	0.58	0.88	0.92	0.96	0.8	0.76	0.88	0.97	0.04	-0.76		0.9	0.34	0.82	0.9
Non Current Liabilities Total	0.95	0.86	0.88	0.9	0.69	0.85	0.8	0.39	0.41	-0.79	0.78	0.46	0.87	0.98	0.87	0.84	0.91	0.87	0.95	0.04	-0.9	0.9		0.49	0.86	0.92
Capital Lease Obligations	0.61	0.83	0.55	0.67	0.59	0.69	0.41	0.95	0.34	-0.49	0.66	0.69	0.67	0.56	0.21	0.7	0.71	0.67	0.48	0.72	-0.72	0.34	0.49		0.66	0.68
Inventory	0.94	0.94	0.89	0.86	0.8	0.99	0.91	0.71	0.27	-0.9	0.88	0.77	0.98	0.87	0.77	0.96	0.96	0.98	0.86	0.32	-0.96	0.82	0.86	0.66		0.95
Other Current Assets	0.99	0.92	0.97	0.86	0.89	0.96	0.87	0.66	0.21	-0.92	0.96	0.69	0.99	0.96	0.83	0.94	0.93	0.99	0.96	0.36	-0.93	0.9	0.92	0.68	0.95

Click cells to compare fundamentals

Maravai Lifesciences Account Relationship Matchups

Maravai Lifesciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	577.8M	1.3B	1.9B	2.3B	1.5B	1.5B
Short Long Term Debt Total	390.2M	590.8M	534.3M	585.3M	611.0M	559.4M
Other Current Liab	18.7M	40.8M	64.3M	88.3M	59.5M	55.1M
Total Current Liabilities	29.6M	130.8M	93.8M	110.1M	87.5M	89.4M
Total Stockholder Equity	141.4M	88.5M	315.5M	545.2M	416.8M	302.8M
Other Liab	15.9M	400.4M	713.6M	693.4M	797.4M	405.2M
Net Tangible Assets	(280.7M)	(313.4M)	315.5M	44.9M	51.6M	54.2M
Property Plant And Equipment Net	94.3M	101.3M	46.3M	116.6M	222.6M	114.4M
Current Deferred Revenue	841K	78.1M	10.2M	3.1M	3.4M	3.2M
Net Debt	365.5M	354.6M	(17.0M)	(46.9M)	36.0M	34.2M
Retained Earnings	(42.4M)	854K	184.6M	404.8M	285.7M	145.8M
Accounts Payable	7.5M	3.0M	8.2M	6.0M	10.7M	7.1M
Cash	24.7M	236.2M	551.3M	632.1M	575.0M	374.2M
Non Current Assets Total	517.2M	939.1M	1.2B	1.4B	787.5M	979.4M
Non Currrent Assets Other	805K	4.2M	52.9M	40.3M	9.3M	8.9M
Other Assets	805K	435.9M	812.5M	806.1M	927.0M	973.4M
Long Term Debt	334.8M	528.6M	524.6M	522.0M	518.7M	506.8M
Cash And Short Term Investments	24.7M	236.2M	551.3M	632.1M	575.0M	374.2M
Net Receivables	18.0M	51.0M	117.5M	146.8M	55.7M	74.3M
Liabilities And Stockholders Equity	577.8M	1.3B	1.9B	2.3B	1.5B	1.5B
Non Current Liabilities Total	403.6M	985.2M	1.3B	1.3B	610.1M	898.5M
Capital Lease Obligations	52.9M	56.2M	3.7M	57.8M	86.8M	47.5M
Inventory	14.2M	33.3M	51.6M	43.2M	51.4M	38.1M
Other Current Assets	3.6M	11.1M	19.7M	25.8M	17.8M	14.6M
Other Stockholder Equity	8.0M	85.1M	128.4M	137.9M	128.5M	90.2M
Total Liab	433.2M	1.1B	1.4B	1.4B	697.6M	987.9M
Net Invested Capital	478.7M	623.1M	846.1M	1.1B	940.9M	814.7M
Property Plant And Equipment Gross	94.3M	101.3M	46.3M	136.1M	254.9M	267.6M
Total Current Assets	60.6M	331.6M	740.0M	847.9M	699.9M	501.2M
Capital Stock	183.9M	2.6M	2.6M	2.6M	2.5M	2.4M
Non Current Liabilities Other	1.2M	2.2M	754.5M	17.4M	2.4M	2.3M
Net Working Capital	31.0M	200.8M	646.3M	737.8M	612.4M	411.8M
Intangible Assets	197.9M	177.7M	117.6M	216.7M	221.0M	210.6M
Common Stock	183.9M	2.6M	2.6M	2.6M	2.5M	2.4M
Property Plant Equipment	94.3M	101.3M	46.3M	116.6M	134.1M	88.2M

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:

How To Invest In Maravai

Details

Is Maravai Stock a good investment?

Details

What is Maravai Lifesciences' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.33)

Earnings Share

(1.67)

Revenue Per Share

2.044

Quarterly Revenue Growth

(0.03)

Return On Assets

(0.02)

The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Maravai Begin Period Cash Flow vs Stock Based Compensation Analysis

Begin Period Cash Flow vs Stock Based Compensation

Begin Period Cash Flow vs Stock Based Compensation Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Stock Based Compensation

Maravai Lifesciences fundamental ratios Correlations

Maravai Lifesciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Maravai Lifesciences fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Other Current Assets	+ 0.99	Total Assets
Cash	+ 0.99	Other Liab
Cash And Short Term Investments	+ 0.99	Other Liab
Inventory	+ 0.99	Other Liab
Other Current Assets	+ 0.99	Cash

Common Stock Total Equity	- 1.0	Long Term Debt
Common Stock Total Equity	- 0.98	Short Long Term Debt Total
Inventory	- 0.96	Common Stock Total Equity
Common Stock Total Equity	- 0.96	Other Assets
Common Stock Total Equity	- 0.96	Total Current Liabilities
Net Debt	- 0.95	Net Tangible Assets